Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials

BACKGROUND. Randomized clinical trials (RCT) that evaluated the addition of lapatinib to trastuzumab plus neoadjuvant chemotherapy (NAC) in patients with HER2-positive, operable breast cancer revealed a questionable improvement in pathologic complete response (pCR) rate. We performed a meta-analysis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Hicks, Mellissa, Macrae, Erin R., Abdel-Rasoul, Mahmoud, Layman, Rachel, Friedman, Susan, Querry, Jenny, Lustberg, Maryam, Ramaswamy, Bhuvaneswari, Mrozek, Ewa, Shapiro, Charles, Wesolowski, Robert
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2015
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4391765/
https://ncbi.nlm.nih.gov/pubmed/25732265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0334
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados